ArticleInfectious medicine2025
Effect of glycemic control on lymphocyte subsets in the dissemination of pulmonary tuberculosis: A retrospective analysis.
Article in Infectious medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extrapulmonary tuberculosis (EPTB) complicates pulmonary tuberculosis (PTB) management. Diabetes mellitus impairs immune function, worsening tuberculosis (TB) outcomes. Methods: This retrospective study investigates the effect of glycemic control on immune function and TB dissemination in 1,768 TB patients (2022-2024). Patients were stratified by glycated hemoglobin (HbA1c) levels (≤ 6% vs. > 6%) and fasting blood glucose (FBG) concentrations (< 7 vs. ≥ 7 mmol/L). Lymphocyte subsets (CD3 Results: Poor glycemic control was associated with lower cell counts of all lymphocyte subsets in patients with PTB (all Conclusions: Poor glycemic control impairs immune cells, while EPTB further reduces immune cell numbers. Integrated glycemic management and immunological monitoring help optimize treatment strategies and improve clinical outcomes, particularly in patients at risk for EPTB.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.